ArticleMedical oncology (Northwood, London, England)2026
MALAT1 promotes autophagy via the mir-28-5p/IGF1R axis in nasopharyngeal carcinoma.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The long non-coding RNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is implicated in cancer progression, yet its precise mechanism in nasopharyngeal carcinoma (NPC), particularly its interaction with microRNAs and its role in regulating autophagy, remains to be fully elucidated. We analyzed MALAT1 and miR-28-5p expression in NPC clinical tissues and assessed their correlation with autophagy markers. The direct binding between MALAT1 and miR-28-5p, and between miR-28-5p and Insulin-like Growth Factor 1 Receptor (IGF1R), was validated using dual-luciferase reporter and RNA immunoprecipitation assays. Functional roles in proliferation, apoptosis, migration, and invasion were determined using Cell Counting Kit-8, flow cytometry, Transwell, and wound healing assays. Autophagic activity was evaluated by measuring microtubule-associated protein 1 A/1B-light chain 3 (LC3)-II/I ratio and p62 levels and observing autophagosome formation. In vivo tumor growth and autophagy were assessed in a xenograft mouse model. We found MALAT1 was significantly upregulated, and miR-28-5p was downregulated in NPC tissues, showing a significant correlation with autophagic activity. MALAT1 functioned as a competitive endogenous RNA by directly binding to and sequestering miR-28-5p. Subsequently, miR-28-5p was shown to directly target and suppress IGF1R. Overexpression of miR-28-5p curbed NPC cell growth, migration, and invasion and promoted apoptosis, whereas MALAT1 overexpression or IGF1R restoration counteracted these effects. The MALAT1/miR-28-5p/IGF1R axis increased the LC3-II/I ratio, decreased p62, and elevated autophagosome formation. These pro-tumorigenic and pro-autophagic effects were consistently observed in vivo. In conclusion, MALAT1 promotes autophagy by sequestering miR-28-5p to upregulate IGF1R in NPC, providing a novel mechanistic insight and a potential therapeutic target.
Indexed as
Identifiers
42360571What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.